Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 39 от 154

Набира участници

International CRDS Registry

Calcium Release Deficiency Syndrome

Calcium Release Deficiency Syndrome (CRDS) is a newly discovered genetic arrhythmia syndrome that confers a risk of life-threatening arrhythmias secondary to RYR2 loss-of-function. The International CRDS registry has been designed to facilitate large-scale evaluation of CRDS, including its phenotypic spectrum, approaches to risk stratification, and optimal treatment strategies.

Начало: 21.11.2024 Край: 31.12.2050

Australia, Belgium, Canada +5 Population Health Research Institute NCT06508164

Набира участници Фаза 2

Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

Prostate Cancer (Post Prostatectomy)

The goal of this clinical trial is to compare 64Cu-SAR-bisPSMA PET/CT and 68Ga PSMA-11 PET/CT in men with biochemical failure following radical prostatectomy. The main questions it aims to answer are: * Is there a difference in the number of lesions of prostate cancer recurrence detected between the 64Cu-SAR-bisPSMA PET/CT and 68Ga PSMA-11 PET/CT scans. * What is the diagnostic accuracy of 64Cu-SAR-bisPSMA PET/CT compared to 68Ga PSMA-11 PET/CT using a standard of care comparator. * Evaluate the magnitude of clinical management change when using 64Cu-SAR-bisPSMA additional to standard of care imaging (68Ga PSMA-11). Participants will: * have 3 visits: 1) standard of care 68Ga PSMA-11 dose and PET/CT scan; 2) 64Cu-SAR-bisPSMA dose and PET/CT; 3) 64Cu-SAR-bisPSMA PET/CT only * have standard of care blood test either at Visit 1 or Visit 2

Начало: 21.11.2024 Край: 01.11.2025 Възраст: от 18 г. Диагностика

Australia St Vincent's Hospital, Sydney NCT06907641

Набира участници Фаза 2

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Epithelial Ovarian Cancer Primary Peritoneal Fallopian Tube Cancer Endometrioid Ovarian Cancer

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

Начало: 20.11.2024 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +8 TORL Biotherapeutics, LLC NCT06690775

Набира участници Фаза 4

Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)

Obesity Knee Osteoarthritis Osteoarthritis, Knee

This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main purpose of this study is to see if tirzepatide can reduce number of these participants who require a knee replacement. Participants will be randomized to take a weekly injection of tirzepatide or a placebo for a total of 72 weeks.

Начало: 19.11.2024 Край: 01.05.2037 Възраст: от 18 г. Лечение

Australia University of Melbourne NCT06191848

Набира участници Фаза 3

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Leukemia

This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).

Начало: 19.11.2024 Край: 26.06.2030 Възраст: 18–70 г. Лечение

Australia, Belgium, Brazil +22 Daiichi Sankyo NCT06578247

Набира участници

A Study to Explore Improved Features and a Simplified Treatment Approach for a Totally Implantable Cochlear Implant (TICI) Research System in Adults With Severe Hearing Loss

Hearing Loss, Bilateral or Unilateral Hearing Loss, Sensorineural Hearing Loss, Cochlear

This clinical study will test a new investigational totally implanted cochlear implant system (TICI G2). The cochlear implant has an implantable microphone under the skin to detect speech and sound from the environment allowing hearing without the need of any external parts. This study will explore new ways to process the sound from the implanted microphone. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve. The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing and overall general health.

Начало: 18.11.2024 Край: 01.11.2027 Възраст: от 18 г. Лечение

Australia Cochlear NCT06642935

Набира участници Фаза 1

A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants

Healthy

The aim of this study is to investigate the safety and tolerability of HB0056 in healthy subjects following single-dose.

Начало: 18.11.2024 Край: 01.10.2025 Възраст: 18–55 г. Друго

New Zealand Shanghai Huaota Biopharmaceutical Co., Ltd. NCT06612970

Набира участници Фаза 3

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).

Начало: 18.11.2024 Край: 08.10.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 AstraZeneca NCT06692738

Набира участници Фаза 2

LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)

Eczema Allergy

The LaCE study is a double-blind, randomised, placebo-controlled trial examining the effectiveness of the probiotic Lactobacillus paracasei LPB27 in treating eczema in young children.

Начало: 15.11.2024 Край: 01.09.2026 Възраст: 3–3 г. Лечение

Australia The University of New South Wales NCT06584552

Набира участници Фаза 2

A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

Diabetic Peripheral Neuropathic Pain

The primary purpose of this study is to evaluate the efficacy of medical cannabis aerosol containing 0.25, 0.5, 1.0 milligrams (mg) delta (Δ)9-tetrahydrocannabinol (THC) inhaled three times a day (TID) compared to placebo via the Fixed-dose Syqe Inhaler on pain intensity at Week 15.

Начало: 14.11.2024 Край: 08.11.2025 Възраст: 18–75 г. Лечение

Australia, Czechia, Germany +2 Syqe Medical NCT06490445

Набира участници Фаза 1

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

Solid Tumor

This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.

Начало: 14.11.2024 Край: 31.05.2028 Възраст: от 18 г. Лечение

Australia, Canada, Israel +5 Genentech, Inc. NCT06619587

Набира участници Фаза 4

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

Staphylococcus Aureus Septicemia Staphylococcus Aureus Bacteremia S. Aureus Bacteremia S. Aureus Bloodstream Infection +1

This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Начало: 14.11.2024 Край: 01.11.2027 Възраст: от 18 г. Лечение

Australia, Canada Todd C. Lee MD MPH FIDSA NCT06637332

Набира участници Фаза 1

Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

HEPATITIS B CHRONIC

This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.

Начало: 14.11.2024 Край: 01.12.2026 Възраст: 18–70 г. Лечение

Hong Kong, Moldova, New Zealand +1 Precision BioSciences, Inc. NCT06680232

Набира участници Фаза 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

Hepatitis B Virus Infection

The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.

Начало: 13.11.2024 Край: 01.09.2027 Възраст: от 18 г. Лечение

Australia, Hong Kong, United States GigaGen, Inc. NCT07024641

Набира участници Фаза 1/2

LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)

Degenerative Disc Disease Lumbar Disc Disease Spine Disease Lumbar Spine Degeneration

The objective of this study is to evaluate the safety and effectiveness of LDGraft (investigational device) compared to 100% human tissue product allograft bone (control) when applied in an ALIF procedure in the treatment of patients with lumbar degenerative disc disease (DDD).

Начало: 12.11.2024 Край: 01.12.2027 Възраст: 22–80 г. Лечение

Australia, United States Locate Bio Pty Ltd NCT06462729

Набира участници Фаза 1/2

A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease

Hyperuricemia Hypouricemia, Renal

This is a phase I/II clinical study to evaluate the safety, tolerability, PK, and efficacy of IG3018 tablet in hyperuricemia (HUA) subjects with or without CKD.

Начало: 12.11.2024 Край: 01.01.2027 Възраст: 18–75 г. Лечение

Australia, Taiwan Intelligem Therapeutics Australia Pty Ltd. NCT06310967

Набира участници Фаза 3

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

Developmental and Epileptic Encephalopathy

This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.

Начало: 11.11.2024 Край: 30.11.2026 Възраст: 2–65 г. Лечение

Australia, Belgium, Brazil +14 Longboard Pharmaceuticals NCT06719141

Набира участници Фаза 1/2

A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

Relapsed Neuroblastoma

Neuroblastoma is one of the most common solid childhood tumours, and a major cause of cancer-related death in children. More than 1200 children/young adults a year are diagnosed in USA and Europe. Around 600 of these cases are considered high-risk, which means the cancer is more difficult to treat successfully. Despite improvements in survival over recent decades, a significant proportion of patients with high-risk neuroblastoma have disease that does not respond to standard treatments (refractory neuroblastoma) or comes back after completion of standard frontline treatment (relapsed neuroblastoma). Therefore, there is a need to develop new treatment strategies and test new drugs to improve outcomes for children with neuroblastoma. Aims Of The BEACON2 Trial * To improve survival for patients with relapsed neuroblastoma by developing new treatment combinations * To evaluate new treatment combinations in relapsed neuroblastoma, within a phase I/II trial that can impact clinical practice, while also allowing dose confirmation for new promising combinations * To evaluate the safety, activity, efficacy and impact on quality of life of these new treatment combinations in relapsed neuroblastoma patients * To improve our understanding of relapsed neuroblastoma biology and advance the development of targeted therapies using biomarkers, by conducting a comprehensive biomarker sample collection. Trial Design BEACON2 is a randomised phase I/phase II, open label, international trial. The trial will have two tiers: Tier 1 will be the main randomisation for two treatment arms initially. Participants will be randomised at trial entry to receive one of the available regimens, treatment A or treatment B. Tier 2 will include smaller dose expansion/confirmation cohorts for more novel experimental treatment combinations (Arm C and future arms), with the potential for them to be moved to Tier 1. Current Tier 1 (Randomisation Tier) Treatment Arms in the BEACON2 Trial: Arm A: dbIT Treatment with dinutuximab beta, irinotecan, and temozolomide, 3 weekly x12 cycles Arm B: BIT Treatment with bevacizumab, irinotecan, and temozolomide, 3 weekly x12 cycles Current Tier 2 (Registration Only Tier) Treatment Arms in the BEACON2 Trial: Arm C: dbBIT Treatment with dinutuximab beta, bevacizumab, irinotecan, and temozolomide, 3 weekly x12 cycles Patient Population and Sample Size Patients aged ≥1 years of age with relapsed neuroblastoma. For each arm in Tier 1, up to 75 patients will be recruited to complete phase 2 investigations. For each arm in Tier 2, 10 patients will be recruited to complete phase I investigations. Approximately 160 participants are initially planned, 75 in each arm of Tier 1 and 10 participants for one dose-confirmation cohort in Tier 2. The study is expected to recruit patients for 3 years, and then finish patient follow-up after an additional 5 years. Translational Sub-study / Biological Studies It is standard of care for patients diagnosed with relapsed neuroblastoma to: * Have had a tumour sample collected at point of initial diagnosis (either during biopsy or surgery) * Have bloods collected before they start and during treatment for their relapsed neuroblastoma * Have a bone aspirate/trephine procedure in order to help confirm relapse. These samples provide very important opportunities for further research, and the study investigators would like to make full use of these opportunities by collecting the analysis already performed on these samples and collect some additional samples (at the same time as the standard ones) to learn and understand more about neuroblastoma and its treatment. Samples will undergo research analysis at the national SIOPEN reference laboratories.

Начало: 11.11.2024 Край: 31.12.2030 Възраст: от 1 г. Лечение

Australia, Belgium, New Zealand +1 University of Birmingham NCT07334301

Набира участници Фаза 3

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused telisotuzumab adizutecan to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met protein above cutoff level refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants are put into treatment arms as part of 2 stages. Each treatment arm in stage 1 receives a different dose of telisotuzumab adizutecan. Each treatment arm in stage 2 receives the optimal dose of telisotuzumab adizutecan or LONSURF plus bevacizumab. Up to approximately 460 adult participants with c-Met protein above cutoff level refractory mCRC, will be enrolled in the study in approximately 160 sites in 15-20 countries. In stage 1, participants will receive intravenously (IV) infused telisotuzumab adizutecan dose A or B. In stage 2, participants will receive the optimal dose of IV infused telisotuzumab adizutecan or the standard of care (SOC), LONSURF oral tablets plus IV infused bevacizumab. The total study duration will be approximately 4 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Начало: 08.11.2024 Край: 01.10.2028 Възраст: от 18 г. Лечение

Australia, Israel, Japan +4 AbbVie NCT06614192

Набира участници Фаза 3

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Metabolic Dysfunction Associated Steatohepatitis

This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with NASH or MASH improve their liver function. Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. All participants regularly receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for up to 4 and a half years. During this time, they visit the study site or have a remote visit by video call every 2, 4 or 6 weeks for about a 1 year and 5 months. After this time participants visit the trial site or have a remote visit every 3 months until the end of the study. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At some visits the liver parameters are measured using different imaging methods. The participants also fill in questionnaires about their symptoms. The results are compared between the groups to see whether the treatment works.

Начало: 07.11.2024 Край: 05.06.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +31 Boehringer Ingelheim NCT06632457

1 … 37 38 39 40 41 … 154